News & Analysis on Clinical Trial Services & Contract Research And Development
News from Novartis, Bayer and Tranzyme – People on the move
By Dan Stanton
- Last updated on
Dr. Jorg Reinhardt. Photo courtesy of Bayer Healthcare
In proposed changes to the Novartis Board of Directors, Dr. Jörg Reinhardt is leaving his post at Bayer Healthcare to become the new Director and designated non-executive Chairman of the Board.
Bayer CEO Dr. Maijn Dekkers said that Reinhardt “has played a major part in the very positive development of Bayer HealthCare in recent years” before wishing him the best at Novartis.
Reinhardt will replace Dr. Daniel Vasella who leaves the Swiss pharma company after 17 years, 14 of which he was CEO. Novartis has also announced that Dr. Verena Briner, Dr. Charles Sawyers, and Mr. William Winters will become three new board members following elections at its AGM in February.
The vacant position of the Chairman of the Bayer Board will be held in the interim by Prof. Wolfgang Plischke who has been a Bayer board member since 2006.
David S. Moore is to become the Chief Business Officer at Tranzyme Pharma, responsible for corporate development. The ex-Vice President of Commercial Operations has been at Tranzyme since leaving Johnson & Johnson in 2011.
Dr. Vipin Garg, Tranzyme CEO, said: “Dave has provided meaningful contributions and leadership since joining Tranzyme,” adding: “I look forward to working with him in his new role as we continue to advance the Company.”
Former President and CEO of Amgen acquisition BioVex, Philip Astley-Sparke, has been appointed President US at Dutch company uniQure.
“Philip’s experience and expertise will be invaluable in building a successful US infrastructure for uniQure,” said Jörn Aldag, CEO of Dutch firm uniQure, as he welcomed the new President US.
Other announcements include:
Robert Forrester has been promoted to President in addition to COO at Verastem. Dr. Christoph Westphal, Chairman and CEO at Verastem said: "Verastem has rapidly progressed through Robert's dedication and outstanding execution across all aspects of the Company."
Pearl Therapeutics appointing Dr. Michael Riebe as Vice President of Pharmaceutical Development and Research. Riebe comes to Pearl from being the Vice President of Research and Development at iCeutica and has previously held several positional at Merck and GlaxoSmithKline.